Rtw Investments 13F: Adds $9.3M to APGE Stake
Rtw Investments has boosted its position in Apogee Therapeutics, adding 70,000 shares valued at approximately $369.3 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rtw Investments added 70,000 shares to its stake in Apogee Therapeutics, Inc. ($APGE), a 2.58% increase, according to a 13F filing with the SEC dated May 15, 2026. It reported 2,782,097 shares worth $369.27 million at the end of the quarter.
Since the filing, $APGE is up 0.0% after 1 week, up 6.2% after 1 month and up 63.5% to date (from the $81.14 close on May 15, 2026).
APGE
Apogee Therapeutics, Inc.
Key Points
- Rtw Investments increased its stake in Apogee Therapeutics (APGE) by 70,000 shares, raising its total to 2,782,097 shares, worth about $369.3 million.
- The stock is currently trading at $132.73, close to its 52-week high of $135.09, reflecting strong investor interest in the biotechnology sector.
- Analysts maintain a 'Hold' rating for Apogee, with a mean price target of $134.62, indicating cautious optimism amidst recent downgrades.
Get $APGE trade alerts by text
We text you when insiders, Congress or big funds trade $APGE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Apogee Therapeutics, Inc. alert may contain errors. Disclosures
Rtw Investments Boosts Position in Apogee Therapeutics
Rtw Investments has increased its stake in Apogee Therapeutics, Inc. (APGE) by 70,000 shares, which brings its total holdings to 2,782,097 shares. This change represents a 2.58% increase, with the total value of the shares now approximately $369.3 million, according to the latest Form 13F filing with the SEC as of May 15, 2026.
What Changed in Rtw's Position
The fund added 70,000 shares to its existing position, growing its stake from 2,712,097 to 2,782,097 shares. This increase shows Rtw's continued confidence in Apogee's potential within the biotechnology industry.
Institutional Activity
No other institutional investors reported changes in their positions for Apogee Therapeutics during this filing period.
How Apogee Therapeutics, Inc. Stock Has Traded
Currently, Apogee Therapeutics is trading at $132.73, which is just below its 52-week high of $135.09. The stock has shown strong performance, particularly as it trades above its 50-day moving average of $134.18, indicating positive momentum in the market.
Recent Earnings
Apogee Therapeutics is set to announce its next earnings report on November 9, 2026. The company has faced challenges with a negative earnings per share of $4.34 and a net margin of 0.0%, reflecting its ongoing development phase in the biotechnology sector.
Insider Buying and Selling at Apogee Therapeutics, Inc.
On June 22, 2026, Chief Medical Officer Carl Dambkowski sold 26,400 shares at an average price of $132.60, totaling around $3.5 million. This transaction was part of a planned selling strategy and does not imply negative sentiment regarding the company's prospects.
Analysts Set New Price Targets
On August 13, 2026, Truist Securities maintained a 'Hold' rating on Apogee with a price target of $135. This follows several downgrades from other firms, including Stifel and Deutsche Bank, which also set a target of $135. The overall analyst consensus remains cautious, with a recommendation key of 'Hold' based on five opinions.
What Apogee Therapeutics, Inc. Does
Apogee Therapeutics develops biologic therapies aimed at treating immunological and inflammatory diseases. Its pipeline includes several promising products targeting conditions like asthma and atopic dermatitis, making it a key player in the healthcare sector.
What's Ahead for Apogee Therapeutics, Inc.
Investors will be watching for the upcoming earnings report in November, which could shed light on the company's financial health. The 13F filing reflects Rtw's holdings as of mid-May and may not represent their current position, so future filings could reveal further changes in strategy.
Related Filing Alerts
Source: Rtw Investments's 13F filing on $APGE (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Rtw Investments 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts